Publication Name	World Journal of Cardiology
Manuscript ID	8482
Country	Argentina

Received	2013-12-28 16:55
Peer-Review Started	2013-12-28 21:08
To Make the First Decision	2014-01-15 16:25
Return for Revision	2014-01-20 13:17
Revised	2014-02-11 06:35
Second Decision	2014-05-19 09:05
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-19 09:19
Articles in Press	2014-05-23 09:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-17 13:55
Publish the Manuscript Online	2014-08-20 20:27

ISSN	1949-8462 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Review
Article Title	Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines
Manuscript Source	Invited Manuscript
All Author List	Cecilia Vasti and Cecilia M Hertig
Funding Agency and Grant Number
Corresponding Author	Cecilia M Hertig, PhD, INGEBI, Laboratory of Molecular Cardiology, Institute for Research in Genetic Engineering and Molecular Biology - Dr. Hector N. Torres- (INGEBI), Vuelta de Obligado 2490, 1428 Buenos Aires,Argentina. chertig@dna.uba.ar
Key Words	Ventricular dilation; Cardiotoxicity; Erbb2; Erbb4; Neuregulin; Trastuzumab; Doxorubicin
Core Tip	We have reviewed the cardiac requirement of neuregulin-1 (NRG1) signaling through the receptor tyrosine kinase erbB2/erbB4. The evidence indicates that the NRG1/erbB signaling pathway displays a panel of activities implicated in maintaining the myocardial architecture during remodeling, which may explain why the combined treatment with antibodies against erbB2 and anthracycline chemotherapy may evolve into a severe dilated cardiomyopathy. We have further examined the potential molecular targets, which have been either inferred from impaired NRG1 signaling or directly assessed by the administration of NRG1. The current working hypotheses have been delineated towards a prospective molecular understanding of NRG1 signaling in heart.
Publish Date	2014-08-20 20:27
Citation	Vasti C, Hertig CM. Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines. World J Cardiol 2014; 6(7): 653-662
URL	http://www.wjgnet.com/1949-8462/full/v6/i7/653.htm
DOI	http://dx.doi.org/10.4330/wjc.v6.i7.653

Full Article (PDF)	WJC-6-653.pdf
Full Article (Word)	WJC-6-653.doc
Manuscript File	8482-Review.doc
Answering Reviewers	8482-Answering reviewers.pdf
Copyright License Agreement	8482-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	8482-Language certificate.pdf
Peer-review Report	8482-Peer review(s).pdf
Scientific Editor Work List	8482-Scientific editor work list.pdf